Αρχειοθήκη ιστολογίου

Πέμπτη 22 Μαρτίου 2018

Applicability of 2008 World Health Organization classification system of hematolymphoid neoplasms: Learning experiences

aboutbul.gif

Sushil Modkharkar, Pooja Navale, Pratibha Kadam Amare, Anuradha Chougule, Nikhil Patkar, Prashant Tembhare, Hari Menon, Manju Sengar, Navin Khattry, Shripad Banavali, Brijesh Arora, Gaurav Narula, Siddhartha Laskar, Nehal Khanna, Mary Ann Muckaden, Venkatesh Rangarajan, Archi Agrawal, Tanuja Shet, Sridhar Epari, PG Subramanian, Sumeet Gujral

Indian Journal of Pathology and Microbiology 2018 61(1):58-65

Background: 2008 World Health Organization (WHO) classification of hematolymphoid neoplasms (HLN) has classified them based on morphology, results of various ancillary techniques, and clinical features.[1] There are no studies looking at the applicability of WHO classification. Aims: The aim of the study was to calculate proportions of all HLN subtypes seen during 1-year period based on 2008 WHO classification of HLN and study applicability and also shortcomings of practices in a tertiary care center in India. Materials and Methods: This was a 1-year retrospective study (January 1st, to December 31st, 2010) where cases were identified using hospital/laboratory electronic records. Old follow-up and referral cases were excluded from the study. Only newly diagnosed cases classified into categories laid down by 2008 WHO classification of HLN included. Results: Out of 2118 newly diagnosed classifiable cases, 1602 (75.6%) cases were of lymphoid neoplasms, 489 (23.1%) cases of myeloid neoplasms, 16 (0.8%) cases of histiocytic and dendritic cell neoplasms, and 11 (0.5%) cases of acute leukemias of ambiguous lineage. Overall, most common HLN subtype was diffuse large B-cell lymphoma (n = 361, 17.0%). Precursor B-lymphoblastic leukaemia/lymphoma (n = 177, 48.2%) was the most common subtype within pediatric age group. Conclusions: All major subtypes of HLN were seen at our center and showed trends almost similar to those seen in other Indian studies. Molecular/cytogenetic studies could not be performed on a significant number of cases owing to logistic reasons (unavailability of complete panels and also cost-related issues) and such cases could not be classified as per the WHO classification system.

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2HZvhO1

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου